Ding Ding1, William Stokes1, Megan Eguchi2, Mohammad Hararah3, Whitney Sumner1, Arya Amini4, Julie Goddard3, Hilary Somerset5, Cathy Bradley2, Jessica McDermott6, David Raben1, Sana D Karam1. 1. Department of Radiation Oncology, University of Colorado Denver, Aurora. 2. Department of Health Systems, Management and Policy, University of Colorado Cancer Center, Aurora. 3. Department of Otolaryngology and Head and Neck Surgery, University of Colorado Denver, Aurora. 4. Department of Radiation Oncology, City of Hope National Medical Center, Duarte, California. 5. Department of Pathology, University of Colorado Denver, Aurora. 6. Division of Medical Oncology, University of Colorado Denver, Aurora.
Abstract
Importance: Oral cavity squamous cell carcinoma (OCSCC) is associated with often-delayed clinical diagnosis, poor prognosis, and expensive therapeutic approaches. Prognostic accuracy is important in improving treatment outcomes of patients with this disease. Objectives: To assess lymph node ratio (LNR) and other factors in estimating response to treatment and provide prognostic information helpful for clinical decision making. Design, Setting, and Participants: A retrospective cohort study was conducted from January 1, 2000, to December 31, 2015, at an academic hospital in Denver, Colorado. Participants included 149 patients with primary OCSCC who received curative-intent surgery and/or postoperative adjuvant therapies. Analysis was performed from December 8, 2017, to August 15, 2018. Main Outcomes and Measures: Overall survival (OS), disease-free survival (DFS), locoregional disease-free survival (LRDFS), and distant metastasis-free survival (DMDFS) adjusted for known prognostic risk factors, as well as correlation of LNR with other histopathologic prognostic factors. Results: Of the 149 patients included in analysis, 105 were men (70.5%); the median age at diagnosis was 59 years (range, 28-88 years). Using the Kaplan-Meier method, the 5-year survival estimates for OS rate was 40.4% (95% CI, 31.3%-49.3%); DFS, 48.6% (95% CI, 38.6%-58.0%); LRDFS, 57.7% (95% CI, 46.6%-67.2%); and DMDFS, 74.7% (95% CI, 65.1%-82.0%). The median follow-up was 20 months for all patients and 34.5 months (range, 0-137 months) for surviving patients. Nonwhite race (hazard ratio [HR], 2.15; 95% CI, 1.22-3.81), T3-T4 category (HR, 1.99; 95% CI, 1.18-3.35), and LNR greater than 10% (HR, 2.71; 95% CI, 1.39-5.27) were associated with poorer OS. Nonwhite patients also had higher risk of locoregional failures (HR, 2.47; 95% CI, 1.28-4.79), whereas women were more likely to have distant metastasis (HR, 2.55; 95% CI, 1.14-5.71). Floor-of-mouth subsite had fewer locoregional recurrences than did other subsites (HR, 0.45, 95% CI, 0.21-0.99). An LNR greater than 10% independently was associated with worse OS (HR, 2.71; 95% CI, 1.39-5.27), DFS (HR, 2.48; 95% CI, 1.18-5.22), and DMDFS (HR, 6.05; 95% CI, 1.54-23.71). The LNR was associated with N-stage (Cramer V, 0.69; 95% CI, 0.58-0.78), extracapsular extension (Cramer V, 0.55; 95% CI, 0.44-0.66), lymphovascular invasion (Cramer V, 0.46; 95% CI, 0.27-0.61); number of excised lymph nodes (Cramer V, 0.24; 95% CI, 0.06-0.37), margin (Cramer V, 0.22; 95% CI, 0.05-0.38), and tumor thickness combined with depth of invasion (Cramer V, 0.25; 95% CI, 0.05-0.38). Conclusions and Relevance: Locoregional treatment failure remained the predominant pattern of failure. An advanced pathologic stage and nonwhite race were found to be associated with worse outcomes. The findings from this study suggest that LNR is the most robust prognostic factor and appears to have implications for risk stratification in this disease.
Importance: Oral cavity squamous cell carcinoma (OCSCC) is associated with often-delayed clinical diagnosis, poor prognosis, and expensive therapeutic approaches. Prognostic accuracy is important in improving treatment outcomes of patients with this disease. Objectives: To assess lymph node ratio (LNR) and other factors in estimating response to treatment and provide prognostic information helpful for clinical decision making. Design, Setting, and Participants: A retrospective cohort study was conducted from January 1, 2000, to December 31, 2015, at an academic hospital in Denver, Colorado. Participants included 149 patients with primary OCSCC who received curative-intent surgery and/or postoperative adjuvant therapies. Analysis was performed from December 8, 2017, to August 15, 2018. Main Outcomes and Measures: Overall survival (OS), disease-free survival (DFS), locoregional disease-free survival (LRDFS), and distant metastasis-free survival (DMDFS) adjusted for known prognostic risk factors, as well as correlation of LNR with other histopathologic prognostic factors. Results: Of the 149 patients included in analysis, 105 were men (70.5%); the median age at diagnosis was 59 years (range, 28-88 years). Using the Kaplan-Meier method, the 5-year survival estimates for OS rate was 40.4% (95% CI, 31.3%-49.3%); DFS, 48.6% (95% CI, 38.6%-58.0%); LRDFS, 57.7% (95% CI, 46.6%-67.2%); and DMDFS, 74.7% (95% CI, 65.1%-82.0%). The median follow-up was 20 months for all patients and 34.5 months (range, 0-137 months) for surviving patients. Nonwhite race (hazard ratio [HR], 2.15; 95% CI, 1.22-3.81), T3-T4 category (HR, 1.99; 95% CI, 1.18-3.35), and LNR greater than 10% (HR, 2.71; 95% CI, 1.39-5.27) were associated with poorer OS. Nonwhite patients also had higher risk of locoregional failures (HR, 2.47; 95% CI, 1.28-4.79), whereas women were more likely to have distant metastasis (HR, 2.55; 95% CI, 1.14-5.71). Floor-of-mouth subsite had fewer locoregional recurrences than did other subsites (HR, 0.45, 95% CI, 0.21-0.99). An LNR greater than 10% independently was associated with worse OS (HR, 2.71; 95% CI, 1.39-5.27), DFS (HR, 2.48; 95% CI, 1.18-5.22), and DMDFS (HR, 6.05; 95% CI, 1.54-23.71). The LNR was associated with N-stage (Cramer V, 0.69; 95% CI, 0.58-0.78), extracapsular extension (Cramer V, 0.55; 95% CI, 0.44-0.66), lymphovascular invasion (Cramer V, 0.46; 95% CI, 0.27-0.61); number of excised lymph nodes (Cramer V, 0.24; 95% CI, 0.06-0.37), margin (Cramer V, 0.22; 95% CI, 0.05-0.38), and tumor thickness combined with depth of invasion (Cramer V, 0.25; 95% CI, 0.05-0.38). Conclusions and Relevance: Locoregional treatment failure remained the predominant pattern of failure. An advanced pathologic stage and nonwhite race were found to be associated with worse outcomes. The findings from this study suggest that LNR is the most robust prognostic factor and appears to have implications for risk stratification in this disease.
Authors: Nabil F Saba; Michael Goodman; Kevin Ward; Chris Flowers; Suresh Ramalingam; Taofeek Owonikoko; Amy Chen; William Grist; Trad Wadsworth; Jonathan J Beitler; Fadlo R Khuri; Dong M Shin Journal: Oncology Date: 2011-09-08 Impact factor: 2.935
Authors: Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre Journal: Head Neck Date: 2005-10 Impact factor: 3.147
Authors: Sabine Reinisch; Astrid Kruse; Marius Bredell; Heinz-Theo Lübbers; Thomas Gander; Martin Lanzer Journal: Ann Surg Oncol Date: 2014-03-21 Impact factor: 5.344
Authors: Jonathan E Leeman; Jin-Gao Li; Xin Pei; Praveen Venigalla; Zachary S Zumsteg; Evangelia Katsoulakis; Eitan Lupovitch; Sean M McBride; Chiaojung J Tsai; Jay O Boyle; Benjamin R Roman; Luc G T Morris; Lara A Dunn; Eric J Sherman; Nancy Y Lee; Nadeem Riaz Journal: JAMA Oncol Date: 2017-11-01 Impact factor: 31.777
Authors: L Giraldi; E Leoncini; R Pastorino; V Wünsch-Filho; M de Carvalho; R Lopez; G Cadoni; D Arzani; L Petrelli; K Matsuo; C Bosetti; C La Vecchia; W Garavello; J Polesel; D Serraino; L Simonato; C Canova; L Richiardi; P Boffetta; M Hashibe; Y C A Lee; S Boccia Journal: Ann Oncol Date: 2017-11-01 Impact factor: 32.976
Authors: Muhammad Faisal; Rahim Dhanani; Sami Ullah; Muhammad Abu Bakar; Nabia Irfan; Kashif Iqbal Malik; Asif Loya; Erovic M Boban; Raza Hussain; Arif Jamshed Journal: Eur Arch Otorhinolaryngol Date: 2020-11-25 Impact factor: 2.503
Authors: Daniella Karassawa Zanoni; Cristina Valero; Marlena R McGill; Pablo H Montero; Jatin P Shah; Richard J Wong; Ian Ganly; Snehal G Patel Journal: Oral Oncol Date: 2021-12-01 Impact factor: 5.972
Authors: Cristina Valero; Daniella K Zanoni; Anjali Pillai; Bin Xu; Nora Katabi; Ronald A Ghossein; Ian Ganly; Luc G T Morris; Jatin P Shah; Richard J Wong; Snehal G Patel Journal: J Surg Oncol Date: 2020-09-24 Impact factor: 3.454
Authors: Ramez Philips; Chihun Han; Brian Swendseid; Joseph Curry; Athanassios Argiris; Adam Luginbuhl; Jennifer Johnson Journal: Front Oncol Date: 2021-07-01 Impact factor: 6.244